Holen Sie sich die Stockscreener-App
7.96
2.31%
0.18
Handel nachbörslich:
8.00
0.04
+0.50%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$7.78
Offen:
$7.67
24-Stunden-Volumen:
1.25M
Relative Volume:
0.46
Marktkapitalisierung:
$363.59M
Einnahmen:
$27.10M
Nettoeinkommen (Verlust:
$-24.31M
KGV:
-9.5904
EPS:
-0.83
Netto-Cashflow:
$-33.33M
1W Leistung:
-12.24%
1M Leistung:
+10.94%
6M Leistung:
-50.09%
1J Leistung:
+104.10%
1-Tages-Spanne:
$7.59
$7.98
1-Wochen-Bereich:
$7.59
$8.60
52-Wochen-Spanne:
$3.84
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Firmenname
Capricor Therapeutics Inc
Sektor
Branche
Telefon
(310) 358-3200
Adresse
10865 ROAD TO THE CURE, SAN DIEGO, CA
Vergleichen Sie CAPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
7.96 | 355.68M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Eingeleitet | Alliance Global Partners | Buy |
| 2025-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | Roth Capital | Buy |
| 2024-10-21 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-26 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-13 | Fortgesetzt | Rodman & Renshaw | Buy |
| 2016-07-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-06-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
Best data tools to analyze Capricor Therapeutics Inc. stockMarket Activity Recap & Weekly Sector Rotation Insights - Newser
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor - Bluefield Daily Telegraph
Live market analysis of Capricor Therapeutics Inc.Rate Hike & Technical Confirmation Trade Alerts - Newser
Applying big data sentiment scoring on Capricor Therapeutics Inc.Share Buyback & AI Powered Market Trend Analysis - Newser
Bragar Eagel & Squire, P.C. Urges Investors in XPLR - GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Investors in XPLR Infrastructure, Centene, Biohaven, or Capricor to Inquire About Their Rights in Class Action Lawsuits - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure ... - Eagle-Tribune
Published on: 2025-08-16 02:13:07 - Newser
Published on: 2025-08-15 23:36:43 - beatles.ru
Capricor Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationCAPR - WV News
Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025CAPR - The Malaysian Reserve
Custom watchlist performance reports with Capricor Therapeutics Inc.New Guidance & Smart Money Movement Alerts - Newser
CAPR FY2025 EPS Estimate Lowered by Cantor Fitzgerald - Defense World
HC Wainwright Issues Pessimistic Estimate for CAPR Earnings - Defense World
Roth Capital Has Bearish Estimate for CAPR Q3 Earnings - Defense World
Class Action Lawsuit Filed Against Capricor Therapeutics, Inc. (CAPR)Recover LossesContact Levi & Korsinsky Before September 15, 2025 - ACCESS Newswire
Transcript : Capricor Therapeutics, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Levi & Korsinsky Notifies Shareholders of Capricor Therapeutics, Inc.(CAPR) of a Class ... - Bluefield Daily Telegraph
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Capricor Therapeutics, Inc.(CAPR) Shareholders - Morningstar
Published on: 2025-08-14 06:24:14 - Newser
Capricor Therapeutics, Inc. Securities Fraud Class Action - GlobeNewswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
Capricor Therapeutics shares rise 1.45% after-hours following a class action lawsuit announcement. - AInvest
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Capricor - GlobeNewswire
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline - ACCESS Newswire
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Capricor Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. – CAPR - FinancialContent
What does recent volatility data suggest for Capricor Therapeutics Inc.Weekly Gains Report & Free Community Consensus Stock Picks - Newser
Lawsuit Alert: Investors who lost money with shares of Capricor - openPR.com
Investors in Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your RightsCAPR - cnhinews.com
CAPR Stock News: Investors with Large Losses Should Contact Robbins LLP to Learn About Leading the Capricor Therapeutics, Inc. Class Action Lawsuit - Morningstar
Capricor Therapeutics Inc (CAPR) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - FinancialContent
Capricor: Q2 Earnings Snapshot - Norwalk Hour
Levi & Korsinsky Reminds Capricor Therapeutics, Inc. - GlobeNewswire
Capricor Therapeutics Inc (CAPR) Q2 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
Capricor Therapeutics: Q2 2025 Financial and Strategic Update - TipRanks
Capricor Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Capricor Therapeutics Q2 2025 sees widened loss, stock dips - Investing.com Australia
Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
A mild market reaction for companies on Prasad’s return - BioWorld MedTech
Vinay Prasad’s Return to FDA Sends Biotech Shares Tumbling - Bloomberg.com
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
Finanzdaten der Capricor Therapeutics Inc-Aktie (CAPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):